- Home
- INFA vs JAZZ Comparison
INFA vs JAZZ Comparison
Compare INFA & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INFA
- JAZZ
- Stock Information
- Founded
- INFA 1993
- JAZZ 2003
- Country
- INFA United States
- JAZZ Ireland
- Employees
- INFA N/A
- JAZZ N/A
- Industry
- INFA EDP Services
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- INFA Technology
- JAZZ Health Care
- Exchange
- INFA Nasdaq
- JAZZ Nasdaq
- Market Cap
- INFA 7.6B
- JAZZ 8.2B
- IPO Year
- INFA 2021
- JAZZ 2007
- Fundamental
- Price
- INFA $24.85
- JAZZ $130.42
- Analyst Decision
- INFA Hold
- JAZZ Strong Buy
- Analyst Count
- INFA 12
- JAZZ 14
- Target Price
- INFA $23.91
- JAZZ $179.71
- AVG Volume (30 Days)
- INFA 1.3M
- JAZZ 658.6K
- Earning Date
- INFA 11-05-2025
- JAZZ 11-05-2025
- Dividend Yield
- INFA N/A
- JAZZ N/A
- EPS Growth
- INFA N/A
- JAZZ N/A
- EPS
- INFA 0.03
- JAZZ N/A
- Revenue
- INFA $1,678,707,000.00
- JAZZ $4,157,832,999.00
- Revenue This Year
- INFA $5.43
- JAZZ $5.80
- Revenue Next Year
- INFA $4.92
- JAZZ $6.06
- P/E Ratio
- INFA $733.48
- JAZZ N/A
- Revenue Growth
- INFA 1.32
- JAZZ 4.14
- 52 Week Low
- INFA $15.65
- JAZZ $95.49
- 52 Week High
- INFA $27.88
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- INFA 49.69
- JAZZ 37.95
- Support Level
- INFA $24.82
- JAZZ $133.45
- Resistance Level
- INFA $24.89
- JAZZ $144.97
- Average True Range (ATR)
- INFA 0.03
- JAZZ 4.19
- MACD
- INFA -0.00
- JAZZ -0.95
- Stochastic Oscillator
- INFA 37.50
- JAZZ 10.02
About INFA Informatica Inc.
Informatica Inc provides artificial intelligence (AI) enabled data management products on a cloud native platform that connects, manages, and unifies data across multi-vendor, multi-cloud, and hybrid systems at an enterprise scale. The company's platform includes a suite of interoperable data management products that leverage the shared services and metadata of the underlying platform, including products for Data Catalog, Data Integration & Engineering, API & Application Integration, Data Quality and Observability, Master Data Management, Customer and Business 360 Applications, Governance, Access and Privacy, and Data Marketplace., allowing customers to track and understand their data. Geographically, the company generates maximum revenue from North America.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.